West Pharmaceutical Services WST Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Halozyme TherapeuticsHALO

$31.88M+10.0%

Cumberland PharmaceuticalsCPIX

$4.71M-7.6%

UFP TechnologiesUFPT

$19.02M+9.3%

TrimasTRS

$41.47M-13.7%

Lifecore Biomedical, Inc.LFCR

$1.31M—

Precision Optics CorporationPOCI

$2.85M+4,885%

FAQ

What is West Pharmaceutical Services's operating lease liabilities (total)?

West Pharmaceutical Services (WST) reported operating lease liabilities (total) of $109.2M in Q2 2026.

How has West Pharmaceutical Services's operating lease liabilities (total) changed year-over-year?

West Pharmaceutical Services's operating lease liabilities (total) increased by 8.4% year-over-year, from $100.7M to $109.2M.

What is the long-term trend for West Pharmaceutical Services's operating lease liabilities (total)?

Over 5 years (2020 to 2025), West Pharmaceutical Services's operating lease liabilities (total) has grown at a 10.9% compound annual growth rate (CAGR), from $70.5M to $118.3M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.